Cai, Junliang
Bristol-Myers Squibb (United States)
3 papers on CoChat
Most cited papers
- Verified
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 357
- Verified
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 198
- Verified
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 139
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free